Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
Diabetes, Obesity and Metabolism,  Clinical Article

Devineni D et al. – In subjects receiving insulin and oral antihyperglycaemic therapy, canagliflozin was well tolerated without evidence for glucose malabsorption, had pharmacokinetic characteristics consistent with once–daily dosing, and improved glycaemic control.

Methods
  • This was a randomized, double-blind, placebo-controlled, parallel-group, 28-day study conducted at two sites, in 29 subjects with T2DM not optimally controlled on insulin and up to one oral antihyperglycaemic agent.
  • Subjects were treated with canagliflozin 100 mg QD or 300 mg twice daily (BID) or placebo.
  • Safety, tolerability, pharmacokinetic characteristics and pharmacodynamic effects of canagliflozin were examined.
  • Glucose malabsorption following a 75-g oral glucose challenge was also examined.

Results
  • Canagliflozin pharmacokinetics were dose-dependent, and the elimination half-life ranged from 12 to 15 h.
  • After 28 days, the renal threshold for glucose excretion was reduced; urinary glucose excretion was increased; and A1C, fasting plasma glucose and body weight decreased in subjects administered canagliflozin (A1C reductions: 0.19% with placebo, 0.73% with 100 mg QD, 0.92% with 300 mg BID; body weight changes: 0.03 kg increase with placebo, 0.73 kg reduction with 100 mg QD, 1.19 kg reduction with 300 mg BID).
  • Glucose malabsorption was not observed with canagliflozin treatment.
  • There were no deaths, serious adverse events or severe hypoglycaemic episodes.
  • The incidence of adverse events was similar across groups.
  • There were no clinically meaningful changes in routine laboratory safety tests, vital signs or electrocardiograms.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Internal Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Internal Medicine Articles

1 Corticosteroid treatment for community-acquired pneumonia - the STEP trial: study protocol for a randomized controlled trial Full Text Trials, July 16, 2014    Free full text    Evidence Based Medicine    Clinical Article

2 Screening pelvic examinations in asymptomatic, average-risk adult women: An evidence report for a clinical practice guideline from the American college of physicians Annals of Internal Medicine, July 2, 2014    Evidence Based Medicine    Clinical Article

3 Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: A randomized clinical trial JAMA, July 10, 2014    Evidence Based Medicine    Clinical Article

4 Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial JAMA Internal Medicine, July 15, 2014    Evidence Based Medicine    Clinical Article

5 Statins and physical activity in older men the osteoporotic fractures in men study JAMA Internal Medicine, June 12, 2014    Evidence Based Medicine    Clinical Article

6 Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials BMJ, June 11, 2014    Evidence Based Medicine    Clinical Article

7 Challenges of infectious diseases in the USA The Lancet, July 3, 2014    Review Article    Clinical Article

8 Vitamin D and Calcium Supplementation to Prevent Fractures in Adults: U.S. Preventive Services Task Force Recommendation Statement Full Text Annals of Internal Medicine, February 26, 2013    Free full text    Clinical Guideline

9 Avoidance of sun exposure is a risk factor for all-cause mortality: results from the MISS cohort Journal of Internal Medicine, April 22, 2014    Evidence Based Medicine    Clinical Article

10 Association between melanocytic nevi and risk of breast diseases: The French E3N Prospective Cohort Full Text PLoS Medicine, July 1, 2014    Free full text    Evidence Based Medicine    Clinical Article

11 Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: A meta-analysis JAMA, June 26, 2014    Evidence Based Medicine    Clinical Article

12 Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial The Lancet, July 25, 2014    Evidence Based Medicine    Clinical Article

13 Changes in circulating leptin levels during acute stress and associations with craving in abstinent smokers: A preliminary investigation Psychoneuroendocrinology, June 20, 2014    Clinical Article

14 CPAP, weight loss, or both for obstructive sleep apnea New England Journal of Medicine, June 13, 2014    Evidence Based Medicine    Clinical Article

15 Treatment of venous thromboembolism Full Text JAMA, February 19, 2014    Free full text    Evidence Based Medicine    Clinical Article

16 Tea consumption and leukemia risk: A meta-analysis Tumor Biology, February 12, 2014    Evidence Based Medicine    Clinical Article

17 Glycated hemoglobin measurement and prediction of cardiovascular disease JAMA, March 26, 2014    Evidence Based Medicine

18 Many sudden cardiac arrests preceded by warning signs Circulation, November 20, 2013    Evidence Based Medicine    Clinical Article

19 Risk of pediatric celiac disease according to HLA haplotype and country New England Journal of Medicine, July 7, 2014    Evidence Based Medicine    Clinical Article

20 Resveratrol levels and all-cause mortality in older community-dwelling adults JAMA Internal Medicine, May 13, 2014    Evidence Based Medicine    Clinical Article

Indexed Journals in Internal Medicine: New England Journal of Medicine, The Lancet, Archives of Internal Medicinemore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close